– USA, MA – Lucy Therapeutics, Inc., a biotech company developing proprietary small molecule therapies for complex neurological diseases, announced the appointment of Kim Drapkin as Board Chair, to help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development.
About Kim Drapkin
Ms. Kim Drapkin brings more than 25 years of experience with private and publicly traded biotechnology and pharmaceutical companies. She most recently served as President and CEO of Graphite Bio, which she successfully merged with LENZ Therapeutics (Nasdaq: LENZ).
Before her work at Graphite Bio and LENZ Therapeutics, Kim Drapkin served as CFO at Jounce Therapeutics, playing a key role in building the company’s financial infrastructure and securing $600 million in financing. She also previously owned a financial consulting firm, where she served as interim CFO for numerous early-stage biotechnology companies, including Jounce, Blueprint Medicines, and other Third Rock Ventures portfolio companies. Before her consulting work, Ms. Drapkin was CFO at EPIX Pharmaceuticals. She also spent a decade in roles of increasing responsibility within the finance organization at Millennium Pharmaceuticals and started her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP.
Kim Drapkin serves on the Boards at Acumen Pharmaceuticals (Nasdaq: ABOS), LENZ Therapeutics (Nasdaq: LENZ), and Imugene Limited (ASX: IMU), chairing the audit committee at both Acumen and Imugene. She served as a board member of Proteostasis and Yumanity Therapeutics.
About Lucy Therapeutics
Lucy Therapeutics is a private biotechnology company in Waltham, MA, founded by Amy Ripka, Ph.D., in 2017, dedicated to unraveling the complex and interrelated biological processes driving central nervous system diseases. Sitting at the center of genetics and mitochondrial function, Lucy Therapeutics is leading the change in how we think about the intersecting pathways that play critical roles in human health and disease, particularly those of the central nervous system, including Rett syndrome, Parkinson’s, and Alzheimer’s disease.
For more information: https://www.lucytherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.